HAEM5:Enteropathy-associated T-cell lymphoma - Revision history

Richard.Glen at 00:49, 26 February 2026

2026-02-26T00:49:15Z

← Older revision		Revision as of 19:49, 25 February 2026
Line 814:		Line 814:
	(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references responsive="0" />		(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references responsive="0" />

	<br /><references />		<br />
			<references />

	==Notes==		==Notes==

Richard.Glen at 00:36, 26 February 2026

2026-02-26T00:36:55Z

← Older revision		Revision as of 19:36, 25 February 2026
Line 814:		Line 814:
	(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references responsive="0" />		(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references responsive="0" />

	<br />		<br /><references />

	==Notes==		==Notes==

Bailey.Glen at 17:14, 3 July 2025

2025-07-03T17:14:20Z

← Older revision		Revision as of 12:14, 3 July 2025
Line 36:		Line 36:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:33, 25 May 2025

2025-05-25T21:33:46Z

← Older revision		Revision as of 16:33, 25 May 2025
Line 149:		Line 149:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 384:		Line 384:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 428:		Line 428:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 473:		Line 473:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration<ref name=":4" /><ref>{{Cite journal\|last=Sh\|first=Swerdlow\|last2=Jr\|first2=Cook\|date=2020\|title=As the world turns, evolving lymphoma classifications-past, present and future\|url=https://pubmed.ncbi.nlm.nih.gov/31493426/\|language=en\|pmid=31493426}}</ref>!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~<ref name=":4" />!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration<ref name=":4" /><ref>{{Cite journal\|last=Sh\|first=Swerdlow\|last2=Jr\|first2=Cook\|date=2020\|title=As the world turns, evolving lymphoma classifications-past, present and future\|url=https://pubmed.ncbi.nlm.nih.gov/31493426/\|language=en\|pmid=31493426}}</ref>!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)<ref name=":4" />!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)
Line 521:		Line 521:
	\|JAK1		\|JAK1
	\|Oncogene		\|Oncogene
	\|23% ~~'''~~48%~~'''~~		\|23% 48%
	\|		\|
	\|		\|
Line 541:		Line 541:
	\|STAT3		\|STAT3
	\|oncogene		\|oncogene
	\|16%, ~~'''~~38%~~'''~~		\|16%, 38%
	\|		\|
	\|		\|
Line 559:		Line 559:
	\|		\|
	\|-		\|-
	\|~~'''~~SOCS3~~'''~~		\|SOCS3
	\|~~'''~~TSG~~'''~~		\|TSG
	\|~~'''~~8%~~'''~~		\|8%
	\|		\|
	\|		\|

Bailey.Glen at 20:10, 25 May 2025

2025-05-25T20:10:07Z

← Older revision		Revision as of 15:10, 25 May 2025
Line 51:		Line 51:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Type I enteropathy-associated T-cell lymphoma
	\|}		\|}

Bailey.Glen at 17:35, 24 March 2025

2025-03-24T17:35:51Z

← Older revision		Revision as of 12:35, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Enteropathy-associated T-cell lymphoma}}		{{DISPLAYTITLE:Enteropathy-associated T-cell lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 14:		Line 13:
	*FNU Monika, MBBS		*FNU Monika, MBBS
	*Andrew Siref, MD		*Andrew Siref, MD
	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Jennelleh at 09:12, 19 February 2025

2025-02-19T09:12:13Z

← Older revision		Revision as of 04:12, 19 February 2025
Line 760:		Line 760:

	*Small intestine (predominantly jejunum and ileum > large intestine and stomach)<ref name=":1" />		*Small intestine (predominantly jejunum and ileum > large intestine and stomach)<ref name=":1" />
	*Dissemination to extra gastrointestinal sites: mesenteric and abdominal lymph nodes > bone marrow, lung, liver or skin<ref name=":2" /><ref>{{Cite journal\|last=Egan\|first=L. J.\|last2=Walsh\|first2=S. V.\|last3=Stevens\|first3=F. M.\|last4=Connolly\|first4=C. E.\|last5=Egan\|first5=E. L.\|last6=McCarthy\|first6=C. F.\|date=1995-09\|title=Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era\|url=https://pubmed.ncbi.nlm.nih.gov/8583077\|journal=Journal of Clinical Gastroenterology\|volume=21\|issue=2\|pages=123–129\|issn=0192-0790\|pmid=8583077}}</ref><ref>{{Cite journal\|last=Malamut\|first=Georgia\|last2=Chandesris\|first2=Olivia\|last3=Verkarre\|first3=Virginie\|last4=Meresse\|first4=Bertrand\|last5=Callens\|first5=Céline\|last6=Macintyre\|first6=Elizabeth\|last7=Bouhnik\|first7=Yoram\|last8=Gornet\|first8=Jean-Marc\|last9=Allez\|first9=Matthieu\|date=2013-05\|title=Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study\|url=https://pubmed.ncbi.nlm.nih.gov/23313469\|journal=Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver\|volume=45\|issue=5\|pages=377–384\|doi=10.1016/j.dld.2012.12.001\|issn=1878-3562\|pmc=7185558\|pmid=23313469}}</ref>.		*Dissemination to extra gastrointestinal sites: mesenteric and abdominal lymph nodes > bone marrow, lung, liver or skin<ref name=":2" /><ref>{{Cite journal\|last=Egan\|first=L. J.\|last2=Walsh\|first2=S. V.\|last3=Stevens\|first3=F. M.\|last4=Connolly\|first4=C. E.\|last5=Egan\|first5=E. L.\|last6=McCarthy\|first6=C. F.\|date=1995-09\|title=Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era\|url=https://pubmed.ncbi.nlm.nih.gov/8583077\|journal=Journal of Clinical Gastroenterology\|volume=21\|issue=2\|pages=123–129\|issn=0192-0790\|pmid=8583077}}</ref><ref name=":14">{{Cite journal\|last=Malamut\|first=Georgia\|last2=Chandesris\|first2=Olivia\|last3=Verkarre\|first3=Virginie\|last4=Meresse\|first4=Bertrand\|last5=Callens\|first5=Céline\|last6=Macintyre\|first6=Elizabeth\|last7=Bouhnik\|first7=Yoram\|last8=Gornet\|first8=Jean-Marc\|last9=Allez\|first9=Matthieu\|date=2013-05\|title=Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study\|url=https://pubmed.ncbi.nlm.nih.gov/23313469\|journal=Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver\|volume=45\|issue=5\|pages=377–384\|doi=10.1016/j.dld.2012.12.001\|issn=1878-3562\|pmc=7185558\|pmid=23313469}}</ref>.
	*Metastases involve intra-abdominal node > bone marrow > lung > liver > skin<ref name=":1" />		*Metastases involve intra-abdominal node > bone marrow > lung > liver > skin<ref name=":1" />
	*CNS (rare)<ref name=":1" />		*CNS (rare)<ref name=":1" />
Line 782:		Line 782:
	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

	*Approximately 25% of EATLs (primarily de novo EATL) are CD8+, and rare cases express TCRγδ ~~[23313469,~~ 26462278]		*Approximately 25% of EATLs (primarily de novo EATL) are CD8+, and rare cases express TCRγδ<ref name=":14" /><ref>{{Cite journal\|last=van Wanrooij\|first=R. L. J.\|last2=de Jong\|first2=D.\|last3=Langerak\|first3=A. W.\|last4=Ylstra\|first4=B.\|last5=van Essen\|first5=H. F.\|last6=Heideman\|first6=D. a. M.\|last7=Bontkes\|first7=H. J.\|last8=Mulder\|first8=C. J. J.\|last9=Bouma\|first9=G.\|date=2015\|title=Novel variant of EATL evolving from mucosal γδ-T-cells in a patient with type I RCD\|url=https://pubmed.ncbi.nlm.nih.gov/26462278\|journal=BMJ open gastroenterology\|volume=2\|issue=1\|pages=e000026\|doi=10.1136/bmjgast-2014-000026\|issn=2054-4774\|pmc=4599158\|pmid=26462278}}</ref>
	*Ki-67 is very low and CD30 is negative in RCDII, their appearance is useful to monitor RCDII progression to EATL and to indicate the need for chemotherapeutic regimens targeting dividing cells, a therapeutic option that is inefficient and even dangerous in RCDII.<ref name=":13" />		*Ki-67 is very low and CD30 is negative in RCDII, their appearance is useful to monitor RCDII progression to EATL and to indicate the need for chemotherapeutic regimens targeting dividing cells, a therapeutic option that is inefficient and even dangerous in RCDII.<ref name=":13" />
	*The most common immunophenotypic profile in EATL is given below:		*The most common immunophenotypic profile in EATL is given below:

Jennelleh at 09:10, 19 February 2025

2025-02-19T09:10:15Z

Jennelleh at 08:58, 19 February 2025

2025-02-19T08:58:41Z

← Older revision		Revision as of 03:58, 19 February 2025
Line 725:		Line 725:

	*Enteropathy-associated T-cell lymphoma (EATL) is an aggressive intestinal T-cell lymphoma more common in patients with celiac disease, especially type II refractory celiac disease (RCDII).		*Enteropathy-associated T-cell lymphoma (EATL) is an aggressive intestinal T-cell lymphoma more common in patients with celiac disease, especially type II refractory celiac disease (RCDII).
	*Most of the EATL cases develop through an intermediate step of RCDII, however it can also arise de novo in patients with celiac disease. <u>33579790</u>		*Most of the EATL cases develop through an intermediate step of RCDII, however it can also arise de novo in patients with celiac disease.<ref name=":13">{{Cite journal\|last=Cording\|first=Sascha\|last2=Lhermitte\|first2=Ludovic\|last3=Malamut\|first3=Georgia\|last4=Berrabah\|first4=Sofia\|last5=Trinquand\|first5=Amélie\|last6=Guegan\|first6=Nicolas\|last7=Villarese\|first7=Patrick\|last8=Kaltenbach\|first8=Sophie\|last9=Meresse\|first9=Bertrand\|date=2022-03\|title=Oncogenetic landscape of lymphomagenesis in coeliac disease\|url=https://pubmed.ncbi.nlm.nih.gov/33579790\|journal=Gut\|volume=71\|issue=3\|pages=497–508\|doi=10.1136/gutjnl-2020-322935\|issn=1468-3288\|pmc=8862029\|pmid=33579790}}</ref>
	*RCDII can be defined as failure to respond to a strict gluten-free diet for at least 12 months and is associated with clonal expansion of immunophenotypically an aberrant IELs <ref name=":5">Govind Bhagat, et al. Enteropathy-associated T-cell lymphoma. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2024 July 2]. (WHO classification of tumors series, 5th ed.; vol. 11). Available from: <nowiki>https://tumourclassification.iarc.who.int/chaptercontent/63/224</nowiki> </ref>, { 33707055 }.		*RCDII can be defined as failure to respond to a strict gluten-free diet for at least 12 months and is associated with clonal expansion of immunophenotypically an aberrant IELs <ref name=":5">Govind Bhagat, et al. Enteropathy-associated T-cell lymphoma. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2024 July 2]. (WHO classification of tumors series, 5th ed.; vol. 11). Available from: <nowiki>https://tumourclassification.iarc.who.int/chaptercontent/63/224</nowiki> </ref><ref>{{Cite journal\|last=Soderquist\|first=Craig R.\|last2=Bhagat\|first2=Govind\|date=2021\|title=Cellular and molecular bases of refractory celiac disease\|url=https://pubmed.ncbi.nlm.nih.gov/33707055\|journal=International Review of Cell and Molecular Biology\|volume=358\|pages=207–240\|doi=10.1016/bs.ircmb.2020.12.001\|issn=1937-6448\|pmid=33707055}}</ref>.
	*Celiac disease may be diagnosed prior to EATL diagnosis in 20-73% of cases, or both entities may be diagnosed concomitantly in 10-58% of the cases<ref name=":5" />		*Celiac disease may be diagnosed prior to EATL diagnosis in 20-73% of cases, or both entities may be diagnosed concomitantly in 10-58% of the cases<ref name=":5" />
	*Risk factors include homozygosity for HLA-DQ2 and advanced age<ref name=":5" />		*Risk factors include homozygosity for HLA-DQ2 and advanced age<ref name=":5" />
Line 782:		Line 782:
	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

	* Approximately 25% of EATLs (primarily de novo EATL) are CD8+, and rare cases express TCRγδ [23313469, 26462278]		*Approximately 25% of EATLs (primarily de novo EATL) are CD8+, and rare cases express TCRγδ [23313469, 26462278]
	*Ki-67 is very low and CD30 is negative in RCDII, their appearance is useful to monitor RCDII progression to EATL and to indicate the need for chemotherapeutic regimens targeting dividing cells, a therapeutic option that is inefficient and even dangerous in RCDII. <~~u>33579790<~~/u>		*Ki-67 is very low and CD30 is negative in RCDII, their appearance is useful to monitor RCDII progression to EATL and to indicate the need for chemotherapeutic regimens targeting dividing cells, a therapeutic option that is inefficient and even dangerous in RCDII.<ref name=":13" />
	* The most common immunophenotypic profile in EATL is given below:		*The most common immunophenotypic profile in EATL is given below:

	Positive (universal) - CD3, CD7		Positive (universal) - CD3, CD7

Jennelleh at 08:53, 19 February 2025

2025-02-19T08:53:13Z

Show changes

← Older revision		Revision as of 04:10, 19 February 2025
Line 734:		Line 734:
	*0.5-1 in 1 million general population (2-5% in patients with celiac disease, 60-80% in patients with refractory celiac disease type 2)<ref name=":6">{{Cite journal\|last=Wh\|first=Verbeek\|last2=Jm\|first2=Van De Water\|last3=A\|first3=Al-Toma\|last4=Jj\|first4=Oudejans\|last5=Cj\|first5=Mulder\|last6=Vm\|first6=Coupé\|date=2008\|title=Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands\|url=https://pubmed.ncbi.nlm.nih.gov/18618372/\|language=en\|pmid=18618372}}</ref><ref name=":1">{{Cite journal\|last=Aj\|first=Ferreri\|last2=Pl\|first2=Zinzani\|last3=S\|first3=Govi\|last4=Sa\|first4=Pileri\|date=2011\|title=Enteropathy-associated T-cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/20655757/\|language=en\|pmid=20655757}}</ref><ref name=":2">{{Cite journal\|last=J\|first=Delabie\|last2=H\|first2=Holte\|last3=Jm\|first3=Vose\|last4=F\|first4=Ullrich\|last5=Es\|first5=Jaffe\|last6=Kj\|first6=Savage\|last7=Jm\|first7=Connors\|last8=L\|first8=Rimsza\|last9=Nl\|first9=Harris\|date=2011\|title=Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project\|url=https://pubmed.ncbi.nlm.nih.gov/21566094/\|language=en\|pmid=21566094}}</ref><ref>{{Cite journal\|last=A\|first=Rubio-Tapia\|last2=Ja\|first2=Murray\|date=2010\|title=Classification and management of refractory coeliac disease\|url=https://pubmed.ncbi.nlm.nih.gov/20332526/\|language=en\|doi=10.1136/gut.2009.195131\|pmc=PMC2861306\|pmid=20332526}}</ref><ref>{{Cite journal\|last=G\|first=Malamut\|last2=P\|first2=Afchain\|last3=V\|first3=Verkarre\|last4=T\|first4=Lecomte\|last5=A\|first5=Amiot\|last6=D\|first6=Damotte\|last7=Y\|first7=Bouhnik\|last8=Jf\|first8=Colombel\|last9=Jc\|first9=Delchier\|date=2009\|title=Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II\|url=https://pubmed.ncbi.nlm.nih.gov/19014942/\|language=en\|pmid=19014942}}</ref>		*0.5-1 in 1 million general population (2-5% in patients with celiac disease, 60-80% in patients with refractory celiac disease type 2)<ref name=":6">{{Cite journal\|last=Wh\|first=Verbeek\|last2=Jm\|first2=Van De Water\|last3=A\|first3=Al-Toma\|last4=Jj\|first4=Oudejans\|last5=Cj\|first5=Mulder\|last6=Vm\|first6=Coupé\|date=2008\|title=Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands\|url=https://pubmed.ncbi.nlm.nih.gov/18618372/\|language=en\|pmid=18618372}}</ref><ref name=":1">{{Cite journal\|last=Aj\|first=Ferreri\|last2=Pl\|first2=Zinzani\|last3=S\|first3=Govi\|last4=Sa\|first4=Pileri\|date=2011\|title=Enteropathy-associated T-cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/20655757/\|language=en\|pmid=20655757}}</ref><ref name=":2">{{Cite journal\|last=J\|first=Delabie\|last2=H\|first2=Holte\|last3=Jm\|first3=Vose\|last4=F\|first4=Ullrich\|last5=Es\|first5=Jaffe\|last6=Kj\|first6=Savage\|last7=Jm\|first7=Connors\|last8=L\|first8=Rimsza\|last9=Nl\|first9=Harris\|date=2011\|title=Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project\|url=https://pubmed.ncbi.nlm.nih.gov/21566094/\|language=en\|pmid=21566094}}</ref><ref>{{Cite journal\|last=A\|first=Rubio-Tapia\|last2=Ja\|first2=Murray\|date=2010\|title=Classification and management of refractory coeliac disease\|url=https://pubmed.ncbi.nlm.nih.gov/20332526/\|language=en\|doi=10.1136/gut.2009.195131\|pmc=PMC2861306\|pmid=20332526}}</ref><ref>{{Cite journal\|last=G\|first=Malamut\|last2=P\|first2=Afchain\|last3=V\|first3=Verkarre\|last4=T\|first4=Lecomte\|last5=A\|first5=Amiot\|last6=D\|first6=Damotte\|last7=Y\|first7=Bouhnik\|last8=Jf\|first8=Colombel\|last9=Jc\|first9=Delchier\|date=2009\|title=Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II\|url=https://pubmed.ncbi.nlm.nih.gov/19014942/\|language=en\|pmid=19014942}}</ref>
	*EATL accounts for 3% of peripheral T-cell lymphomas and represents 66% of all primary intestinal T-cell lymphomas<ref name=":5" />		*EATL accounts for 3% of peripheral T-cell lymphomas and represents 66% of all primary intestinal T-cell lymphomas<ref name=":5" />
	*More common in regions with a high prevalence of CD, particularly Europe (0.05–0.14 cases per 100 000 population) { 15825131 ; 20197551 ~~; 18618372~~ } and the USA (0.016 cases per 100 000 population)		*More common in regions with a high prevalence of CD, particularly Europe (0.05–0.14 cases per 100 000 population)<ref>{{Cite journal\|last=Catassi\|first=Carlo\|last2=Bearzi\|first2=Italo\|last3=Holmes\|first3=Geoffrey K. T.\|date=2005-04\|title=Association of celiac disease and intestinal lymphomas and other cancers\|url=https://pubmed.ncbi.nlm.nih.gov/15825131\|journal=Gastroenterology\|volume=128\|issue=4 Suppl 1\|pages=S79–86\|doi=10.1053/j.gastro.2005.02.027\|issn=0016-5085\|pmid=15825131}}</ref><ref>{{Cite journal\|last=Sieniawski\|first=Michal\|last2=Angamuthu\|first2=Nithia\|last3=Boyd\|first3=Kathryn\|last4=Chasty\|first4=Richard\|last5=Davies\|first5=John\|last6=Forsyth\|first6=Peter\|last7=Jack\|first7=Fergus\|last8=Lyons\|first8=Simon\|last9=Mounter\|first9=Philip\|date=2010-05-06\|title=Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation\|url=https://pubmed.ncbi.nlm.nih.gov/20197551\|journal=Blood\|volume=115\|issue=18\|pages=3664–3670\|doi=10.1182/blood-2009-07-231324\|issn=1528-0020\|pmid=20197551}}</ref><ref name=":6" /> and the USA (0.016 cases per 100 000 population)
	*Extremely rare in Asia due to low population frequency of celiac HLA risk alleles<ref name=":6" /><ref name=":1" /><ref name=":2" />		*Extremely rare in Asia due to low population frequency of celiac HLA risk alleles<ref name=":6" /><ref name=":1" /><ref name=":2" />
	*> 60% of all cases in intestinal T- cell lymphomas<ref name=":6" /><ref name=":1" /><ref name=":2" />		*> 60% of all cases in intestinal T- cell lymphomas<ref name=":6" /><ref name=":1" /><ref name=":2" />
Line 746:		Line 746:

	*CD can be diagnosed at the time of EATL diagnosis<ref name=":5" />		*CD can be diagnosed at the time of EATL diagnosis<ref name=":5" />
	*Patients with RCD can sometimes present with small-intestinal ulceration (ulcerative jejunitis) { 9250161 ; 10381521 }.		*Patients with RCD can sometimes present with small-intestinal ulceration (ulcerative jejunitis)<ref>{{Cite journal\|last=Ashton-Key\|first=M.\|last2=Diss\|first2=T. C.\|last3=Pan\|first3=L.\|last4=Du\|first4=M. Q.\|last5=Isaacson\|first5=P. G.\|date=1997-08\|title=Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/9250161\|journal=The American Journal of Pathology\|volume=151\|issue=2\|pages=493–498\|issn=0002-9440\|pmc=1857986\|pmid=9250161}}</ref><ref>{{Cite journal\|last=Bagdi\|first=E.\|last2=Diss\|first2=T. C.\|last3=Munson\|first3=P.\|last4=Isaacson\|first4=P. G.\|date=1999-07-01\|title=Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population\|url=https://pubmed.ncbi.nlm.nih.gov/10381521\|journal=Blood\|volume=94\|issue=1\|pages=260–264\|issn=0006-4971\|pmid=10381521}}</ref>.

	If there is no prior diagnosis of celiac disease and lymphoma is the initial presentation, the following findings can point towards celiac disease associated EATL:		If there is no prior diagnosis of celiac disease and lymphoma is the initial presentation, the following findings can point towards celiac disease associated EATL:
Line 760:		Line 760:

	*Small intestine (predominantly jejunum and ileum > large intestine and stomach)<ref name=":1" />		*Small intestine (predominantly jejunum and ileum > large intestine and stomach)<ref name=":1" />
	*Dissemination to extra gastrointestinal sites: mesenteric and abdominal lymph nodes > bone marrow, lung, liver or skin { 8583077 ; 23313469 ~~; 21566094~~ }.		*Dissemination to extra gastrointestinal sites: mesenteric and abdominal lymph nodes > bone marrow, lung, liver or skin<ref name=":2" /><ref>{{Cite journal\|last=Egan\|first=L. J.\|last2=Walsh\|first2=S. V.\|last3=Stevens\|first3=F. M.\|last4=Connolly\|first4=C. E.\|last5=Egan\|first5=E. L.\|last6=McCarthy\|first6=C. F.\|date=1995-09\|title=Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era\|url=https://pubmed.ncbi.nlm.nih.gov/8583077\|journal=Journal of Clinical Gastroenterology\|volume=21\|issue=2\|pages=123–129\|issn=0192-0790\|pmid=8583077}}</ref><ref>{{Cite journal\|last=Malamut\|first=Georgia\|last2=Chandesris\|first2=Olivia\|last3=Verkarre\|first3=Virginie\|last4=Meresse\|first4=Bertrand\|last5=Callens\|first5=Céline\|last6=Macintyre\|first6=Elizabeth\|last7=Bouhnik\|first7=Yoram\|last8=Gornet\|first8=Jean-Marc\|last9=Allez\|first9=Matthieu\|date=2013-05\|title=Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study\|url=https://pubmed.ncbi.nlm.nih.gov/23313469\|journal=Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver\|volume=45\|issue=5\|pages=377–384\|doi=10.1016/j.dld.2012.12.001\|issn=1878-3562\|pmc=7185558\|pmid=23313469}}</ref>.
	*Metastases involve intra-abdominal node > bone marrow > lung > liver > skin<ref name=":1" />		*Metastases involve intra-abdominal node > bone marrow > lung > liver > skin<ref name=":1" />
	*CNS (rare)<ref name=":1" />		*CNS (rare)<ref name=":1" />